AU2003286555A8 - Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases - Google Patents
Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseasesInfo
- Publication number
- AU2003286555A8 AU2003286555A8 AU2003286555A AU2003286555A AU2003286555A8 AU 2003286555 A8 AU2003286555 A8 AU 2003286555A8 AU 2003286555 A AU2003286555 A AU 2003286555A AU 2003286555 A AU2003286555 A AU 2003286555A AU 2003286555 A8 AU2003286555 A8 AU 2003286555A8
- Authority
- AU
- Australia
- Prior art keywords
- arteriosclerosis
- disease
- nitric oxide
- fibrotic diseases
- oxide modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 208000004362 Penile Induration Diseases 0.000 title 1
- 208000020758 Peyronie disease Diseases 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003176 fibrotic effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940125745 nitric oxide modulator Drugs 0.000 title 1
- 150000004713 phosphodiesters Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42028102P | 2002-10-22 | 2002-10-22 | |
US60/420,281 | 2002-10-22 | ||
PCT/US2003/033400 WO2004037183A2 (en) | 2002-10-22 | 2003-10-21 | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003286555A1 AU2003286555A1 (en) | 2004-05-13 |
AU2003286555A8 true AU2003286555A8 (en) | 2004-05-13 |
Family
ID=32176545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003286555A Abandoned AU2003286555A1 (en) | 2002-10-22 | 2003-10-21 | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003286555A1 (en) |
WO (1) | WO2004037183A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004038328A1 (en) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | New uses of 2-phenyl-substituted imidazotriazinone derivatives |
CN101106997A (en) | 2004-08-17 | 2008-01-16 | 约翰·霍普金斯大学 | PDE5 inhibitor compositions and methods for treating cardiac indications |
TWI339578B (en) | 2004-10-29 | 2011-04-01 | Mitsubishi Tanabe Pharma Corp | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions |
KR100914445B1 (en) * | 2005-06-10 | 2009-08-28 | 동아제약주식회사 | Agent for prevention and treatment of liver diseases comprising pyrazolopyrimidinone derivative |
EP2219650B1 (en) * | 2007-10-26 | 2014-05-07 | Pacific Therapeutics Ltd. | Compositions and methods for treating fibroproliferative disorders |
MX350145B (en) | 2011-07-20 | 2017-08-28 | Mediwound Ltd | Proteolytic extract from bromelain for the treatment of connective tissue disorders. |
EP2938343B1 (en) | 2012-12-21 | 2018-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
AU2015101954A4 (en) * | 2015-01-06 | 2020-04-30 | Harrow Ip, Llc | Pharmaceutical formulations of xanthine or xanthine derivatives |
CA3055882A1 (en) | 2017-03-14 | 2018-09-20 | Atir Holding S.A. | Topical formulation for the treatment of pigmented skin |
CA3055881C (en) | 2017-03-14 | 2021-04-06 | Atir Holding S.A. | Use of heterocyclic compounds in the treatment of pigmented skin |
CN112773898A (en) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | Application of phosphodiesterase 5 inhibitor in preparing anti-fibrosis disease medicine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4430128A1 (en) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Combination preparation with immunosuppressive, cardiovascular and cerebral effects |
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US5824669A (en) * | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
-
2003
- 2003-10-21 AU AU2003286555A patent/AU2003286555A1/en not_active Abandoned
- 2003-10-21 WO PCT/US2003/033400 patent/WO2004037183A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004037183A3 (en) | 2004-08-05 |
AU2003286555A1 (en) | 2004-05-13 |
WO2004037183A2 (en) | 2004-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7186501A (en) | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases | |
AU2001275177A1 (en) | Cardiac disease treatment and device | |
AU2001253565A1 (en) | Cardiac disease treatment and device | |
AU2001275176A1 (en) | Cardiac disease treatment and device | |
HUS1500069I1 (en) | Ophthalmologic irrigation solutions and method | |
EP1416961A4 (en) | Composition and method for the treatment of disease | |
AU2003256253A8 (en) | Aerosol for medical treatment and methods | |
EP1551399A4 (en) | Method for topical treatment of eye disease and composition and device for said treatment | |
AU2002257151A1 (en) | Health care payment and compliance management | |
AU2003290548A1 (en) | Prevention and treatment of synucleinopathic disease | |
HK1070849A1 (en) | Catheter and use method thereof | |
HUP0401605A3 (en) | Integrin inhibitors for the treatment of eye diseases | |
AU2003286555A8 (en) | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases | |
AU2002237667A1 (en) | Methods for the treatment and prevention of urinary stone disease | |
ZA200307475B (en) | Carbamate compounds for use in the treatment of pain. | |
AU2002220266A1 (en) | Methods for the identification and the treatment of cardiovascular disease | |
MXPA03006776A (en) | Use of il-18 inhibitors for the treatment and/or prevention of heart disease. | |
GB2383537B (en) | Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith | |
AU2003237657A1 (en) | Means and methods for improved treatment using "setrones" | |
AUPQ582400A0 (en) | A method of treatment and agents for use therein | |
EP1438431A4 (en) | Methods for diagnosing and treating heart disease | |
ZA200209632B (en) | Methods for prevention of ulcers and improving physiological performance. | |
AU2002365941A8 (en) | Methods of diagnosis, monitoring and treatment of fertility | |
EP1408808A4 (en) | Methods for diagnosing and treating heart disease | |
AU2003245674A1 (en) | Oral disease prevention and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |